The Human Apolipoprotein AV Gene Is Regulated by Peroxisome Proliferator-activated Receptor-α and Contains a Novel Farnesoid X-activated Receptor Response Element
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
The newly identified apolipoprotein AV (apoAV) gene is a key player in determining plasma triglyceride concentrations. Because hypertriglyceridemia is a major independent risk factor in coronary artery disease, the understanding of the regulation of the expression of this gene is of considerable importance. We presently characterize the structure, the transcription start site, and the promoter of the human apoAV gene. Since the peroxisome proliferator-activated receptor-alpha (PPARalpha) and the farnesoid X-activated receptor (FXR) have been shown to modulate the expression of genes involved in triglyceride metabolism, we evaluated the potential role of these nuclear receptors in the regulation of apoAV transcription. Bile acids and FXR induced the apoAV gene promoter activity. 5'-Deletion, mutagenesis, and gel shift analysis identified a heretofore unknown element at positions -103/-84 consisting of an inverted repeat of two consensus receptor-binding hexads separated by 8 nucleotides (IR8), which was required for the response to bile acid-activated FXR. The isolated IR8 element conferred FXR responsiveness on a heterologous promoter. On the other hand, in apoAV-expressing human hepatic Hep3B cells, transfection of PPARalpha specifically enhanced apoAV promoter activity. By deletion, site-directed mutagenesis, and binding analysis, a PPARalpha response element located 271 bp upstream of the transcription start site was identified. Finally, treatment with a specific PPARalpha activator led to a significant induction of apoAV mRNA expression in hepatocytes. The identification of apoAV as a PPARalpha target gene has major implications with respect to mechanisms whereby pharmacological PPARalpha agonists may exert their beneficial hypotriglyceridemic actions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Activation of PPARα increases the production of lipoprotein lipase (LPL) and apolipoprotein (apo) A-V, while it decreases the plasma levels of apo C-III that inhibits LPL activity, thereby enhancing the catabolism of TG-rich lipoproteins and reducing serum TG levels [31–34].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636
Identification of a nuclear receptor that is activated by farnesol metabolites
Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90530-8 · Cited by 1,210
Schoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Research works printed but not linked: 2
- Desvergne, B., and Wahli, W. (1999) Endocr. Rev. 20, 649 -688
- Applied Biosystems (2001) User Bulletin 2, Foster City, CA
Cited by
Peroxisome Proliferator-Activated Receptor Alpha Target Genes
Rakhshandehroo, M., Knoch, B., Müller, M., & Kersten, S. (2010) · PPAR Research · doi:10.1155/2010/612089 · Cited by 1,020
“Secondly, PPARα agonists increase hepatic expression and plasma levels of APOA5, which is a positive regulator of LPL [220].”
BackgroundBile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935
“Activation of FXR induces apolipoprotein (Apo) CII and ApoA5, which are LPL activators carried by VLDL, and represses ApoCIII, which is an LPL inhibitor (Kast et al., 2001; Claudel et al., 2003; Prieur et al., 2003).”
BackgroundIntegrated physiology and systems biology of PPARα
Kersten, S. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.02.002 · Cited by 670
“Consistent with this finding, APOA5 mRNA is induced by PPARa activation in human and monkey hepatocytes, and APOA5 plasma levels are increased by treatment of monkeys with a synthetic PPARa agonist [173,253,254].”
BackgroundPhysiological regulation of lipoprotein lipase
Kersten, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.03.013 · Cited by 550
“There is compelling data that stimulation of LPL-mediated plasma TG clearance by fibrates may be mediated by upregulation of APOA5, which has been shown to be a direct PPARα target gene in humans but not in mice [40–42].”
BackgroundRegulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms
Chiang, J. Y. L. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2003.11.006 · Cited by 546
Bile acid metabolism and signaling, the microbiota, and metabolic disease
Cai, J., Rimal, B., Jiang, C., Chiang, J. Y. L., & Patterson, A. D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108238 · Cited by 497
The Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism
Claudel, T., Staels, B., & Kuipers, F. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000178994.21828.a7 · Cited by 504
Comparative Analysis of Gene Regulation by the Transcription Factor PPARα between Mouse and Human
Rakhshandehroo, M., Hooiveld, G., Müller, M., & Kersten, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006796 · Cited by 305
“Previously, it was shown that APOA1, APOA2 and APOA5 are upregulated by PPARa agonists, which was found to be specific for humans [38–41].”
BackgroundSchaap, F. G., Rensen, P. C. N., Voshol, P. J., Vrins, C., van der Vliet, H. N., Chamuleau, R. A. F. M., Havekes, L. M., Groen, A. K., & van Dijk, K. W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403240200 · Cited by 300
PPAR-α as a Key Nutritional and Environmental Sensor for Metabolic Adaptation
Contreras, A. V., Torres, N., & Tovar, A. R. (2013) · Advances in Nutrition · doi:10.3945/an.113.003798 · Cited by 236
Copple, B. L., & Li, T. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.12.007 · Cited by 235
Fruchart, J.-C. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.008 · Cited by 233
O’Brien, P. J., Alborn, W. E., Sloan, J. H., Ulmer, M., Boodhoo, A., Knierman, M. D., Schultze, A. E., & Konrad, R. J. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.040824 · Cited by 215
“It was also recently shown that ApoA5 mRNA expression is regulated by peroxisome proliferator-activated receptor(PPAR- ) agonists, suggesting that ApoA5 may be the long-sought mechanism by which this class of compounds decreases serum triglycerides (22, 23).”
BackgroundBile Acids and FXR: Novel Targets for Liver Diseases
Stofan, M., & Guo, G. L. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00544 · Cited by 197
The importance of gene–environment interactions in human obesity
Reddon, H., Guéant, J.-L., & Meyre, D. (2016) · Clinical Science · doi:10.1042/cs20160221 · Cited by 203
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5
Fruchart-Najib, J., Baugé, E., Niculescu, L.-S., Pham, T., Thomas, B., Rommens, C., Majd, Z., Brewer, B., Pennacchio, L. A., & Fruchart, J.-C. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.05.003 · Cited by 198
“Finally, PPARα agonists are known to have hypotriglyceridemic effect, and recent studies have shown that the APOA5 gene is highly up-regulated by PPARα and FXR [15, 16].”
BackgroundDUVAL, C., MULLER, M., & KERSTEN, S. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.05.003 · Cited by 199
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191
Benefit of farnesoid X receptor inhibition in obstructive cholestasis
Stedman, C., Liddle, C., Coulter, S., Sonoda, J., Alvarez, J. G., Evans, R. M., & Downes, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604772103 · Cited by 170
Mikael, L. G., Genest, J., & Rozen, R. (2006) · Circulation Research · doi:10.1161/01.res.0000204825.66410.0b · Cited by 163
Lai, C.-Q., Demissie, S., Cupples, L. A., Zhu, Y., Adiconis, X., Parnell, L. D., Corella, D., & Ordovas, J. M. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400192-jlr200 · Cited by 163
Bile acids and their receptors
Martinot, E., Sèdes, L., Baptissart, M., Lobaccaro, J.-M., Caira, F., Beaudoin, C., & Volle, D. H. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.01.006 · Cited by 162
Willems van Dijk, K., Rensen, P. C., Voshol, P. J., & Havekes, L. M. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200406000-00002 · Cited by 154
Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism
Kersten, S. (2008) · PPAR Research · doi:10.1155/2008/132960 · Cited by 149
“A functional PPAR responsive element has been identified in the promoter of the human APOA5 gene, classifying APOA5 as a direct PPARα target gene [62, 63].”
Penney, N. C., Kinross, J. K., Newton, R. C., & Purkayastha, S. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.115 · Cited by 159
Lai, C.-Q., Tai, E.-S., Tan, C. E., Cutter, J., Chew, S. K., Zhu, Y.-P., Adiconis, X., & Ordovas, J. M. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300251-jlr200 · Cited by 138
“(29) and Prieur, Coste, and Rodriguez (30)”
Fatehi-Hassanabad, Z., & Chan, C. B. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-1 · Cited by 135
The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk
Lai, C.-Q., Parnell, L. D., & Ordovas, J. M. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000162320.54795.68 · Cited by 137
Apolipoprotein A-V-heparin Interactions
Lookene, A., Beckstead, J. A., Nilsson, S., Olivecrona, G., & Ryan, R. O. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501589200 · Cited by 130
Farnesoid X Receptor: From Structure to Potential Clinical Applications
Pellicciari, R., Costantino, G., & Fiorucci, S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0582221 · Cited by 130
FXR-mediated regulation of eNOS expression in vascular endothelial cells
Li, J., Wilson, A., Kuruba, R., Zhang, Q., Gao, X., He, F., Zhang, L.-M., Pitt, B. R., Xie, W., & Li, S. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvm016 · Cited by 124
Apolipoprotein A-V; a potent triglyceride reducer
Nilsson, S. K., Heeren, J., Olivecrona, G., & Merkel, M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.07.019 · Cited by 139
Determination of the Functionality of Common APOA5 Polymorphisms
Talmud, P. J., Palmen, J., Putt, W., Lins, L., & Humphries, S. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502144200 · Cited by 117
Lai, C.-Q., Corella, D., Demissie, S., Cupples, L. A., Adiconis, X., Zhu, Y., Parnell, L. D., Tucker, K. L., & Ordovas, J. M. (2006) · Circulation · doi:10.1161/circulationaha.105.577296 · Cited by 117
Corella, D., Lai, C., Demissie, S., Cupples, L. A., Manning, A. K., Tucker, K. L., & Ordovás, J. M. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0147-0 · Cited by 110
“Other potential mechanisms may involve a different regulation of the APOA5 gene by thyroid hormones [34] or PPARs [33], depending on the promoter allele and the fat intake.”
BackgroundNowak, M., Helleboid-Chapman, A., Jakel, H., Martin, G., Duran-Sandoval, D., Staels, B., Rubin, E. M., Pennacchio, L. A., Taskinen, M.-R., Fruchart-Najib, J., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.4.1537-1548.2005 · Cited by 107
APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency
Calandra, S., Oliva, C. P., Tarugi, P., & Bertolini, S. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000217892.00618.54 · Cited by 103
The functions of gut microbiota-mediated bile acid metabolism in intestinal immunity
He, Y., Shaoyong, W., Chen, Y., Li, M., Gan, Y., Sun, L., Liu, Y., Wang, Y., & Jin, M. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.05.015 · Cited by 124
“Here, FXR reduced serum TG by promoting the expression of ApoCII, which activates lipoprotein lipase (LPL), while inhibiting the expression of ApoCIII, an LPL inhibitor [161–163].”
A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration
Ishihara, M., Kujiraoka, T., Iwasaki, T., Nagano, M., Takano, M., Ishii, J., Tsuji, M., Ide, H., Miller, I. P., Miller, N. E., et al. (2005) · Journal of Lipid Research · doi:10.1194/jlr.d500018-jlr200 · Cited by 97
Thibaut, R., Gage, M. C., Pineda‐Torra, I., Chabrier, G., Venteclef, N., & Alzaid, F. (2022) · The FEBS Journal · doi:10.1111/febs.15877 · Cited by 95
Genetics of familial combined hyperlipidemia and risk of coronary heart disease
Shoulders, C. C. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh069 · Cited by 95
“A recent report appears to rule out the involvement of the less common allele at the APOA5 locus (115), while data from transgenic mice (116,117), gene expression studies (115,118, 119) and genome-wide linkage studies (12,56) suggest that the causative lesion(s) may operate through a mechanism perturbing transcription…”
BackgroundVaessen, S. F. C., Schaap, F. G., Kuivenhoven, J.-A., Groen, A. K., Hutten, B. A., Boekholdt, S. M., Hattori, H., Sandhu, M. S., Bingham, S. A., Luben, R., et al. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600233-jlr200 · Cited by 93
Jakel, H., Nowak, M., Moitrot, E., Dehondt, H., Hum, D. W., Pennacchio, L. A., Fruchart-Najib, J., & Fruchart, J.-C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404744200 · Cited by 93
Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective
Feng, H., & Chen, Y. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i33.7463 · Cited by 94
Apolipoproteins A-IV and A-V are acute-phase proteins in mouse HDL
Khovidhunkit, W., Duchateau, P. N., Medzihradszky, K. F., Moser, A. H., Naya-Vigne, J. M., Shigenaga, J. K., Kane, J. P., Grünfeld, C., & Feingold, K. R. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.04.018 · Cited by 94
“More recently, apo A-V has been shown to be regulated by PPAR- and FXR [38,39].”
BackgroundBile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development
Li, T., & Chiang, J. Y. L. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000978 · Cited by 90
Thyroid Hormone Regulates the Hypotriglyceridemic Gene APOA5
Prieur, X., Huby, T., Coste, H., Schaap, F. G., Chapman, M. J., & Rodríguez, J. C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503139200 · Cited by 83
Self-citationHu, T., Chouinard, M., Cox, A. L., Sipes, P., Marcelo, M., Ficorilli, J., Li, S., Gao, H., Ryan, T. P., Michael, M. D., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606779200 · Cited by 83
ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition
Chen, Y. Q., Pottanat, T. G., Zhen, E. Y., Siegel, R. W., Ehsani, M., Qian, Y.-W., & Konrad, R. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100068 · Cited by 82
Prediction of genetic risk for metabolic syndrome
Yamada, Y., Kato, K., Hibino, T., Yokoi, K., Matsuo, H., Segawa, T., Watanabe, S., Ichihara, S., Yoshida, H., Satoh, K., et al. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.05.035 · Cited by 83
Sánchez-Moreno, C., Ordovás, J. M., Smith, C. E., Baraza, J. C., Lee, Y., & Garaulet, M. (2011) · Journal of Nutrition · doi:10.3945/jn.110.130344 · Cited by 75
Su, X., Kong, Y., & Peng, D. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0833-2 · Cited by 79
Meta-analysis of primary target genes of peroxisome proliferator-activated receptors
Heinäniemi, M., Uski, J. O., Degenhardt, T., & Carlberg, C. (2007) · Genome Biology · doi:10.1186/gb-2007-8-7-r147 · Cited by 71
“This cluster comprises the genes APOA2 [45], APOA5 [46], fatty acid desaturase 1 (FADS2) [47], pregnane X receptor (PXR) [48], RVRα and solute carrier (SLC) 10A2 [49].”
BackgroundZhao, M., Jiafeng, Z., Yang, H., Ouyang, Z., Lv, C., Geng, Z., & Zhao, J. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118182 · Cited by 73
Peroxisome Proliferator-Activated Receptor α in Lipid Metabolism and Atherosclerosis
Yu, X., Zheng, X., & Tang, C. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2015.06.005 · Cited by 71
“A functional PPRE has been identified in the promoter of the human apoA-V gene, suggesting that apoA-V functions as a direct target gene of PPARα [30].”
BackgroundFXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells
Zhang, Q., He, F., Kuruba, R., Gao, X., Wilson, A. S., Li, J., Billiar, T. R., Pitt, B. R., Xie, W., & Li, S. (2007) · Cardiovascular Research · doi:10.1093/cvr/cvm068 · Cited by 71
Bi, N., Sheng-kai, Y., Li, G., Yin, Z.-N., & Chen, B. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.06.017 · Cited by 62
Degenhardt, T., Matilainen, M., Herzig, K.-H., Dunlop, T. W., & Carlberg, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605623200 · Cited by 62
Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome
Maász, A., Kisfali, P., Horvatovich, K., Mohás, M., Markó, L., Csöngei, V., Faragó, B., Járomi, L., Magyari, L., Sáfrány, E., et al. (2007) · Pathology & Oncology Research · doi:10.1007/bf02893505 · Cited by 61
Mechanism of action of anti-hypercholesterolemia drugs and their resistance
Tiwari, V., & Khokhar, M. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.048 · Cited by 68
PPAR-α agonists are still on the rise: an update on clinical and experimental findings
Ferri, N., Corsini, A., Sirtori, C., & Ruscica, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1312339 · Cited by 55
“The effect of PPAR-α activators on the metabolism of TGrich lipoproteins is due to a PPAR-α-dependent stimulation of lipoprotein lipase (LPL) activity of apolipoprotein (apo)A-V [38] and to an inhibition of apoC3 expression, a causal CVD risk factor, whereas the increase in plasma HDL-C depends partly on an overexpres…”
BackgroundYamada, Y., Ichihara, S., Kato, K., Yoshida, T., Yokoi, K., Matsuo, H., Watanabe, S., Metoki, N., Yoshida, H., Satoh, K., et al. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2007.052415 · Cited by 60
“Systolic blood pressure, mmHg 140 (25) 142 (26) 143 (24) 0.”
InfluentialHavasi, V., Szolnoki, Z., Talián, G. C., Bene, J., Komlósi, K., Maász, A., Somogyvári, F., Kondacs, A., Szabó, M., Fodor, L., et al. (2006) · Journal of Molecular Neuroscience · doi:10.1385/jmn:29:2:177 · Cited by 61
Schaap, F. G., Nierman, M. C., Berbée, J. F. P., Hattori, H., Talmud, P. J., Vaessen, S. F. C., Rensen, P. C. N., Chamuleau, R. A. F. M., Kuivenhoven, J. A., & Groen, A. K. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m500533-jlr200 · Cited by 58
“For example, among medication taken by some of the subjects in the current HTG group, lipidlowering fibrates have been shown to upregulate apoa5 mRNA levels in vitro (33, 34).”
BackgroundRuiz-Narváez, E., Yang, Y., Nakanishi, Y., Kirchdorfer, J., & Campos, H. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500040-jlr200 · Cited by 61
Transcriptional Regulation of Apolipoprotein A5 Gene Expression by the Nuclear Receptor RORα
Genoux, A., Dehondt, H., Helleboid‐Chapman, A., Duhem, C., Hum, D. W., Martin, G., Pennacchio, L. A., Staels, B., Fruchart‐Najib, J., & Fruchart, J. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000163841.85333.83 · Cited by 56
Liu, H., Zhang, S., Lin, J., Li, H., Huang, A., Xiao, C., Li, X., Su, Z., Wang, C., Nebert, D. W., et al. (2005) · Metabolism · doi:10.1016/j.metabol.2004.11.009 · Cited by 55
Balasubramaniam, D., Schroeder, O., Russell, A. M., Fitchett, J. R., Austin, A. K., Beyer, T. P., Chen, Y., Day, J. W., Ehsani, M. E., Heng, A. R., et al. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100198 · Cited by 56
Rodriguez, M. A. D. L. R., Sugahara, G., Hooiveld, G. J. E. J., Ishida, Y., Tateno, C., & Kersten, S. (2018) · BMC Genomics · doi:10.1186/s12864-018-4834-3 · Cited by 54
“Similarly, APOA5 was identified as a direct PPARα target and was shown to be induced by PPARα activators in human and cynomolgus hepatocytes [43, 44].”
BackgroundBettzieche, A., Brandsch, C., Weiße, K., Hirche, F., Eder, K., & Stangl, G. I. (2008) · British Journal of Nutrition · doi:10.1017/s0007114507857266 · Cited by 51
Medicinal Chemistry Of Farnesoid X Receptor Ligands: From Agonists And Antagonists To Modulators
Merk, D., Steinhilber, D., & Schubert‐Zsilavecz, M. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.47 · Cited by 52
Treviño-Villarreal, J. H., Reynolds, J. S., Bartelt, A., Langston, P. K., MacArthur, M. R., Arduini, A., Tosti, V., Veronese, N., Bertozzi, B., Brace, L. E., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99470 · Cited by 52
“These include repression by the liver X-receptor (LXR)/SREBP-1c (32) and induction by peroxisome proliferator-activated receptor α (PPARα) (33), thyroid hormone receptor (34), and cAMP-responsive”
BackgroundCocci, P., Mosconi, G., Arukwe, A., Mozzicafreddo, M., Angeletti, M., Aretusi, G., & Palermo, F. A. (2015) · Chemical Research in Toxicology · doi:10.1021/tx500529x · Cited by 53
Mattei, J., Demissie, S., Tucker, K. L., & Ordovás, J. M. (2009) · Journal of Nutrition · doi:10.3945/jn.109.109900 · Cited by 49
The role of apolipoprotein A5 in non-alcoholic fatty liver disease
Ress, C., Moschen, A. R., Sausgruber, N., Tschoner, A., Graziadei, I., Weiss, H., Schgoer, W., Ebenbichler, C. F., Konrad, R. J., Patsch, J. R., et al. (2011) · Gut · doi:10.1136/gut.2010.222224 · Cited by 56
Upregulation of scavenger receptor class B type I expression by activation of FXR in hepatocyte
Fan, C., Gong, W., Zheng, Y., Li, Y., Huang, G., Gao, M., Li, J., Kuruba, R., Gao, X., Li, S., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.09.016 · Cited by 47
Ahn, H. Y., Kim, M., Ahn, Y.-T., Sim, J.-H., Choi, I.-D., Lee, S.-H., & Lee, J. H. (2015) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.05.002 · Cited by 44
Dai, W., Zhang, Z., Yao, C., & Zhao, S. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1166-5 · Cited by 47
“been found critical to direct its expression in human hepatic cell lines [13, 14].”
BackgroundIdentification of DRIP205 as a Coactivator for the Farnesoid X Receptor
Pineda Torra, I., Freedman, L. P., & Garabedian, M. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405126200 · Cited by 43
Wright, W. T., Young, I. S., Nicholls, D., Patterson, C. C., Lyttle, K., & Graham, C. A. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.06.043 · Cited by 44
The farnesoid X receptor: a novel drug target?
Claudel, T., Sturm, E., Kuipers, F., & Staels, B. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.9.1135 · Cited by 47
“Moreover, the promoter of the Apo A-V gene [84] was also shown to be transactivated by FXR via an IR-8 FXRE [85].”
BackgroundInfluentialSchultze, A. E., Alborn, W. E., Newton, R. K., & Konrad, R. J. (2005) · Journal of Lipid Research · doi:10.1194/jlr.c500010-jlr200 · Cited by 43
Gilde, A. J., Fruchart, J., & Staels, B. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.097 · Cited by 49
Yamashita, S., Rizzo, M., Su, T., & Masuda, D. (2023) · Metabolites · doi:10.3390/metabo13050626 · Cited by 44
Palmen, J., Smith, A. J. P., Dorfmeister, B., Putt, W., Humphries, S. E., & Talmud, P. J. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.03.003 · Cited by 45
Is apolipoprotein A5 a novel regulator of triglyceride‐rich lipoproteins?
Jäkel, H., Nowak, M., Helleboid‐Chapman, A., Fruchart‐Najib, J., & Fruchart, J. (2006) · Annals of Medicine · doi:10.1080/07853890500407488 · Cited by 51
“(16) reported that FXR and bile acids activate the APOA5 promoter.”
BackgroundInfluentialOng, K. L., Jiang, C. Q., Liu, B., Jin, Y. L., Tso, A. W. K., Tam, S., Wong, K. S., Tomlinson, B., Cheung, B. M. Y., Lin, J. M., et al. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03899.x · Cited by 40
Prieur, X., Schaap, F. G., Coste, H., & Rodríguez, J. C. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0048 · Cited by 43
Self-citationSeko, Y., Yamaguchi, K., Umemura, A., Yano, K., Takahashi, A., Okishio, S., Kataoka, S., Okuda, K., Moriguchi, M., Okanoue, T., et al. (2020) · Hepatology Research · doi:10.1111/hepr.13571 · Cited by 43
Matsunaga, A., Arishima, H., Niimura, H., Zhang, B., Uehara, Y., Ohwaki, K., Morita, M., Hayashida, K., & Saku, K. (2007) · Circulation Journal · doi:10.1253/circj.71.746 · Cited by 38
Huang, X., Zhao, S., Bai, L., Hu, M., Zhao, W., & Zhang, Q. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00350.x · Cited by 36
“PPAR-a, a ligand-activated transcription factor, has been implicated in the up-regulation of apoAV gene expression, and a functional PPAR response element in the proximal apoAV promoter has been detected using deletion and mutagenesis analyses (Prieur et al., 2003; Vu-Dac et al., 2003).”
BackgroundMethodMaász, A., Kisfali, P., Szolnoki, Z., Hadarits, F., & Melegh, B. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0768-z · Cited by 35
Kreeft, A. J., Moen, C. J. A., Porter, G., Kasanmoentalib, S., Shiri‐Sverdlov, R., van Gorp, P. J., Havekes, L. M., Frants, R. R., & Hofker, M. H. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.01.049 · Cited by 34
Trauner, M., & Boyer, J. L. (2004) · Current Opinion in Gastroenterology · doi:10.1097/00001574-200405000-00006 · Cited by 36
Hallman, D. M., Srinivasan, S. R., Chen, W., Boerwinkle, E., & Berenson, G. S. (2006) · Metabolism · doi:10.1016/j.metabol.2006.07.018 · Cited by 33
Mitogen-activated protein kinase pathway
(2004) · Springer eBooks · doi:10.1007/3-540-29662-x_1853 · Cited by 32
Sheng-kai, Y., Cheng, X., Yao-hong, S., Xiao, X., Bi, N., & Chen, B. (2005) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2005.105 · Cited by 31
“(19) demonstrated that APOA5 gene expression could be enhanced markedly by fibrates through the peroxisome proliferator-activated receptor (PPAR)a pathway, signal transmission of which requires the participation of the PPAR response element.”
BackgroundFruchart, J., Hermans, M. P., Fruchart‐Najib, J., & Kodama, T. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00897-x · Cited by 30
Determinants of Plasma Apolipoprotein A-V and APOA5 Gene Transcripts in Humans
Hahne, P., Krempler, F., Schaap, F., Soyal, S., Höffinger, H., Miller, K., Oberkofler, H., Strobl, W., & Patsch, W. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01987.x · Cited by 32
Jiang, C. Q., Liu, B., Cheung, B. M. Y., Lam, T. H., Lin, J. M., Jin, Y. L., Yue, X. J., Ong, K. L., Tam, S., Wong, K. S., et al. (2010) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.93 · Cited by 32
Metadata
- Authors
- Prieur, X., Coste, H., & Rodríguez, J. C.
- Affiliations
- GlaxoSmithKline (France) (FR)
- Corresponding author
- Rodríguez, Joan C.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-07
- Volume
- 278
- Issue
- 28
- Pages
- 25468-25480
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2032849264
- Cited by
- 194
- References
- 55
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 8 · 2014: 8 · 2013: 5 · 2012: 6
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6302 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- PPARα, farnesoid X receptor, bile acids, transcriptional regulation, promoter structure, transcription start sites, hypertriglyceridemia, hepatic gene expression, PPARα agonist, hypotriglyceridemic effect, triglyceride metabolism
- MeSH terms
- Apolipoprotein A-V, Receptor, Farnesoid X-Activated, Apolipoproteins, Apolipoproteins A, Base Sequence, Cell Line, Cell Nucleus, Chromosome Mapping, DNA-Binding Proteins, Exons, Carcinoma, Hepatocellular, Humans, Introns, Luciferases, Models, Genetic, Molecular Sequence Data, Mutation, Plasmids, DNA Ligases, Promoter Regions, Genetic, RNA, Messenger, Transcription Factors, Transcription, Genetic, Transfection, Protein Biosynthesis, Transcriptional Activation, Mutagenesis, Site-Directed, Gene Deletion, Receptors, Cytoplasmic and Nuclear, Receptors, Retinoic Acid, Dimerization, 5' Untranslated Regions, Reverse Transcriptase Polymerase Chain Reaction, Response Elements, Hepatocytes, Retinoid X Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.